Jubilant Pharmova Limited
Jubilant Pharmova Limited (JUBLPHARMA.NS) Stock Overview
Explore Jubilant Pharmova Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
142.1B
P/E Ratio
32.85
EPS (TTM)
$27.25
ROE
0.07%
JUBLPHARMA.NS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Jubilant Pharmova Limited (JUBLPHARMA.NS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 40.87, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1023.06.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 32.85 and a market capitalization of 142.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.